Skip to main content
. 2022 Aug 22;13:900864. doi: 10.3389/fgene.2022.900864

TABLE 1.

Clinical factors of STAS_positive and STAS_negative groups.

Factors Overall (n = 19) Positive (n = 11) Negative (n = 8) p-value
Age group (years, %) ≥60 11 (57.9) 7 (63.6) 4 (50.0) 0.658
<60 8 (42.1) 4 (36.4) 4 (50.0)
Gender (%) Female 9 (47.4) 4 (36.4) 5 (62.5) 0.37
Male 10 (52.6) 7 (63.6) 3 (37.5)
Tumor_size (cm) Median [IQR] 2.00 [1.35, 3.00] 2.50 [1.50, 3.00] 1.75 [1.15, 2.62] 0.558
N_stage (%) N0 17 (89.5) 9 (81.8) 8 (100.0) 0.228
N2 2 (10.5) 2 (18.2) 0 (0.0)
p stage (%) IA1 4 (21.1) 2 (18.2) 2 (25.0) 0.454
IA2 5 (26.3) 2 (18.2) 3 (37.5)
IA3 7 (36.8) 5 (45.5) 2 (25.0)
IB 1 (5.3) 0 (0.0) 1 (12.5)
IIIA 2 (10.5) 2 (18.2) 0 (0.0)
Smoking (%) No 11 (57.9) 6 (54.5) 5 (62.5) 1
Yes 8 (42.1) 5 (45.5) 3 (37.5)
EGFR (%) Mutant-type 4 (21.1) 2 (18.2) 2 (25.0) 1
Wild-type 15 (78.9) 9 (81.8) 6 (75.0)
ALK (%) Mutant-type 4 (21.1) 3 (27.3) 1 (12.5) 0.603
Wild-type 15 (78.9) 8 (72.7) 7 (87.5)
KRAS (%) Mutant-type 4 (21.1) 3 (27.3) 1 (12.5) 0.603
Wild-type 15 (78.9) 8 (72.7) 7 (87.5)